▶주메뉴 바로가기
▶본문 바로가기
[THE INVESTOR] LG Chem said on Nov. 12 that it will expand its drug portfolio to immuno oncology by forging a partnership with US biotech Cue Biopharma. With the exclusive license deal, LG Chem wi...
[THE INVESTOR] Korea’s leading biosimilar manufacturer Celltrion said on Nov.9 its third-quarter net profit plunged 49 percent from a year earlier due to price cuts and reduced output. Net profi...
[THE INVESTOR] Democratic Party lawmaker Park Yong-jin revealed on Nov. 7 a handful of documents that were exchanged between Samsung BioLogics and the control tower of Samsung regarding the contract...
[THE INVESTOR] Samsung BioLogics said on Nov. 6 it is close to wrapping up an asset transfer deal with US-based Biogen to sell its shares in their joint venture Samsung Bioepis. Samsung BioLogics w...
[THE INVESTOR] Korea’s GC Pharma said on Nov. 5 that its US subsidiary Curevo has received approval from the US Food and Drug Administration to begin phase 1 clinical trials of CRV-101, its vaccine ...
[THE INVESTOR] Korean pharmaceutical company Yuhan said on Nov. 5 that it has signed a deal with Janssen Biotech to license out Lazertinib, a novel clinical-stage therapeutic candidate for the treat...
[THE INVESTOR] Celltrion Healthcare , the marketing arm of Celltrion, said on Nov. 2 that it has won big tenders for Herzuma, its biosimilar version of Roche’s blockbuster breast drug Herceptin in ...
[THE INVESTOR] Bukwang Pharmaceutical said on Oct. 31 US biotech Acer Therapeutics has submitted a New Drug Application with the US Food and Drug Administration for its drug candidate EDSIVO, a tre...
[THE INVESTOR] Korean pharmaceutical firm Samsung Bioepis has started research on a biosimilar for the drug Soliris, used to treat paroxysmal nocturnal hemoglobinuria, industry sources said on Oct. ...
[THE INVESTOR] Genexine and its US affiliate NeoImmuneTech said on Oct. 30 that the US Food and Drug Administration has approved its Investigational New Drug application for clinical trials of its ...
[THE INVESTOR] Hanmi Pharmaceuticals said on Oct. 30 that its partner Athenex will initiate clinical trials next year on an oncology drug candidate that has utilized its platform. The New York-bas...
[THE INVESTOR] SK Plasma said on Oct. 30 it has started operations at its new Andong plant, raising the company’s production capacity of plasma derivatives by nearly 500 percent. The 31,586-squa...
[THE INVESTOR] JW Pharmaceutical said on Oct. 29 it will invest 2 million pounds (US$2.57 million) in UK biotechnology firm Argonaut Therapeutics which develops epigenetically-acting drugs for the t...
[THE INVESTOR] Korean cosmetics giant Amorepacific said on Oct. 29 that its third-quarter net profit fell 39.8 percent from a year earlier on increased one-off costs. For the three months ended ...
[THE INVESTOR] HanAll Biopharma , a subsidiary of Daewoong Pharmaceutical, said on Oct. 29 it plans to begin phase 3 clinical trials for its anti-TNF ophthalmic solution HM036 in 2019 after complet...
European nations pitch to attract Korean startups at EXIT Daejeon 2019
Exit Daejeon 2019 ingrains international mindset in Korean startups
Startup CEOs pitch at DAEJEON 2019 forum
VCs, accelerators and entrepreneurs share insights on startup ecosystem
Finding right people is key to growth of startups: Slush founder
Global startup community leaders take Daejeon by storm
'Foldable display ready for commercialization': LGD CTO
MSCI appoints Tay Kim as chief of Korean unit
May 23, 2019
